June 24, 2025 11:12 AM EDT
R&D

Nek­tar's mid-stage eczema da­ta de­liv­er key win in bid for com­pa­ny turn­around

Max Gelman

Senior Editor

Nek­tar Ther­a­peu­tics is blaz­ing a come­back trail for a drug it once worked on with Eli Lil­ly, trum­pet­ing pos­i­tive Phase 2b da­ta on Tues­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: FDA's Makary sought re­jec­tion of KalVista’s drug in an un­usu­al move by com­mis­sion­er, sources say

RFK Jr. says he did not com­mit to up­hold­ing ACIP ros­ter to se­cure Cas­sidy’s back­ing

Rev­o­lu­tion inks up to $2B 'flex­i­ble' fund­ing deal to ad­vance RAS in­hibitor pipeline

Ar­riVent plots next steps for lung can­cer drug; Neu­ron23's $96.5M raise

Up­dat­ed: Am­gen plans low­er, slow­er Mar­i­Tide dos­es for obe­si­ty drug’s Phase 3

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times